 Home > Medical News > Latest Medical News > Baiyunshan Pharmaceutical Amlodipine Besylate Tablets have passed the quality and efficacy consistency evaluation of generic drugs

Baiyunshan Pharmaceutical Amlodipine Besylate Tablets have passed the quality and efficacy consistency evaluation of generic drugs

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

pharmaceutical glaze

jobs pharmaceutical industry

pharmaceutical companies india

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 9, Baiyunshan Pharmaceutical issued an announcement stating that the branch Baiyunshan Pharmaceutical General Factory received the "Drug Supplementary Application Approval Notice" issued by NMPA.
Amlodipine besylate tablets have passed the quality and efficacy consistency evaluation of generic drugs.

.

Amlodipine besylate is a dihydropyridine calcium antagonist used to treat essential hypertension, chronic stable angina and variant angina
.

Baiyunshan Pharmaceutical General Factory Amlodipine Besylate was officially launched in China in October 2007, and the consistency evaluation application was submitted to the National Medical Products Administration on September 26, 2019, and it was accepted on October 25, 2019.

At present, the manufacturers of amlodipine besylate tablets listed in China also include Pfizer Pharmaceuticals Co.
, Ltd.
, China Resources SECCO Pharmaceutical Co.
, Ltd.
, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical Co.
, Ltd.
, Zhejiang Jianfeng Pharmaceutical Co.
, Ltd.
, Kunmingsainuo pharmaceutical Co.
, Ltd.
and so on
.

According to data from Minai.

As of the announcement date, Baiyunshan Pharmaceutical General Factory has invested approximately RMB 4,378,800 in research and development expenses (unaudited) for the consistency evaluation of the drug
.

The sales revenue of the drug from the Baiyunshan Pharmaceutical General Factory in 2019 was RMB 1.

If this article violates your rights, please contact us

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.